Recent research into sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide – 1 (GLP-1) receptor agonists have revealed significant impacts on body fat distribution and have the potential to redefine the medical management of obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.